Suppr超能文献

血管内栓塞保护在隐静脉移植介入中的局限性:202 例连续患者的见解。

Limitations of embolic protection in saphenous vein graft intervention: insights from 202 consecutive patients.

机构信息

Cardioquest, Tampa, FL, USA.

出版信息

J Interv Cardiol. 2009 Jun;22(3):240-6. doi: 10.1111/j.1540-8183.2009.00465.x. Epub 2009 Apr 14.

Abstract

Between January 2003 and September 2006, a total of 2,541 patients had percutaneous coronary intervention (PCI). Of these, 202 (226 grafts) had at least one saphenous vein graft (SVG) intervention. Adjunctive distal embolic protection (DEP) devices were attempted in 123 SVGs (54.4%). The 30-day major adverse cardiac event (occurrence of death, myocardial infarction, or target vessel revascularization) rate in the overall group was 11.9%. The presence of angiographic thrombus independently predicted DEP use while the presence of in-stent restenosis predicted no DEP use. Although the presence of all angiographic technical feasibility criteria independently predicted DEP use, only 72 (32.4%) and 33 (14.6%) of the SVGs would have been eligible for the occlusive balloon- and filter-based distal embolic criteria, respectively. The most common technical reason for ineligibility was a graft size smaller than 3.0 mm, followed by the lack of a long enough landing zone. In a subset of 21 (9.3%) completely occluded lesions which would have excluded DEP use, angiographic success was 66.7%, and that was predicated on successful debulking with rheolytic thrombectomy in 13 (61.9%) with subsequent DEP in 5 (23.8%). In conclusion, not all grafts can be protected, and even in those that can, such protection may be incomplete. Newer embolic protection devices, such as the Proxis((R)), were recently introduced to expand the applicability to a wider population of vein grafts. However, further design improvements such as device miniaturizations applicable to sub-3.0-mm vessels and better particle removing/filtering mechanisms are needed in order to expand the use of embolic protection to reduce the persistently high complication rates associated with this difficult- to-treat subset of patients.

摘要

2003 年 1 月至 2006 年 9 月期间,共有 2541 名患者接受了经皮冠状动脉介入治疗(PCI)。其中,202 名(226 个移植物)至少有一条隐静脉移植物(SVG)介入。在 123 个 SVG 中尝试了辅助远端栓塞保护(DEP)装置(54.4%)。总体组 30 天主要不良心脏事件(死亡、心肌梗死或靶血管血运重建)发生率为 11.9%。存在血管造影血栓独立预测 DEP 使用,而存在支架内再狭窄预测不使用 DEP。尽管所有血管造影技术可行性标准的存在均独立预测 DEP 使用,但只有 72 个(32.4%)和 33 个(14.6%)SVG 分别符合闭塞球囊和基于滤器的远端栓塞标准。无资格获得 DEP 的最常见技术原因是移植物尺寸小于 3.0mm,其次是缺乏足够长的着陆区。在 21 个(9.3%)完全闭塞病变的亚组中,排除 DEP 使用,血管造影成功率为 66.7%,这是在 13 个(61.9%)成功使用旋切血栓切除术进行减容的基础上实现的,随后在 5 个(23.8%)中使用 DEP。总之,并非所有移植物都可以得到保护,即使在可以保护的移植物中,这种保护也可能不完全。最近推出了新型栓塞保护装置,如 Proxis((R)),旨在将适用性扩大到更广泛的静脉移植物人群。然而,需要进一步的设计改进,如适用于小于 3.0mm 血管的设备小型化和更好的颗粒去除/过滤机制,以扩大栓塞保护的使用,降低与这一难以治疗的患者亚组相关的高并发症发生率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验